0001299933-14-001357.txt : 20140902 0001299933-14-001357.hdr.sgml : 20140901 20140902172857 ACCESSION NUMBER: 0001299933-14-001357 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20140827 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20140902 DATE AS OF CHANGE: 20140902 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLASE, INC CENTRAL INDEX KEY: 0000811240 STANDARD INDUSTRIAL CLASSIFICATION: DENTAL EQUIPMENT & SUPPLIES [3843] IRS NUMBER: 870442441 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36385 FILM NUMBER: 141078378 BUSINESS ADDRESS: STREET 1: 4 CROMWELL CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-361-1200 MAIL ADDRESS: STREET 1: 4 CROMWELL CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: BIOLASE TECHNOLOGY INC DATE OF NAME CHANGE: 19941117 FORMER COMPANY: FORMER CONFORMED NAME: LASER MEDICAL TECHNOLOGY INC DATE OF NAME CHANGE: 19941117 FORMER COMPANY: FORMER CONFORMED NAME: LASER ENDO TECHNIC CORP DATE OF NAME CHANGE: 19920708 8-K 1 htm_50425.htm LIVE FILING Biolase, Inc. (Form: 8-K)  

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   August 27, 2014

Biolase, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

     
Delaware 000-19627 87-0442441
_____________________
(State or other jurisdiction 		_____________
(Commission 		______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
4 Cromwell, Irvine, California   92618
_________________________________
(Address of principal executive offices) 		  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   949-361-1200

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 27, 2014, the Board of Directors (the "Board") of Biolase, Inc. (the "Company") appointed Jeffrey M. Nugent as President and permanent Chief Executive Officer of the Company. Mr. Nugent has served as Acting Chief Executive Officer since June 16, 2014. Mr. Nugent's compensation arrangement, as previously disclosed in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on July 17, 2014, remains unchanged. Effective August 27, 2014, Alexander K. Arrow resigned as President and Chief Operating Officer of the Company and was named Chief Medical Officer of the Company.








Item 7.01 Regulation FD Disclosure.

On September 2, 2014, the Company issued press releases announcing the appointment of Mr. Jeffrey M. Nugent as President and permanent Chief Executive Officer, and the appointment of Dr. Alexander K. Arrow as Chief Medical Officer, copies of which are attached as Exhibits 99.1 and 99.2 respectively, to this Current Report on Form 8-K.





Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. See "Exhibit Index" attached to this Current Report on Form 8-K, which is incorporated by reference.





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    Biolase, Inc.
          
September 2, 2014   By:   /s/ Frederick D. Furry
       
        Name: Frederick D. Furry
        Title: Chief Financial Officer

Exhibit Index


     
Exhibit No.   Description
 
99.1
  Press Release of Biolase, Inc., dated August 2, 2014.
99.2
  Press Release of Biolase, Inc., dated August 2, 2014.
EX-99.1 2 exhibit1.htm EX-99.1 EX-99.1

NEWS RELEASE

BIOLASE NAMES JEFFREY M. NUGENT PERMANENT PRESIDENT
AND CHIEF EXECUTIVE OFFICER

Nugent Previously Served as Acting CEO since June;
Will Focus on Expanding Company’s Global Leadership in Dental Lasers

IRVINE, CA (September 2, 2014) — BIOLASE, Inc. (NASDAQ:BIOL), the world’s leading manufacturer and distributor of dental lasers, today announced that Jeffrey M. Nugent has been named President and Chief Executive Officer by the Company’s Board of Directors, effective immediately. Nugent has served as Acting Chief Executive Officer and a member of the Board of Directors since June 2014.

Nugent has a broad background in the medical device, medical laser technology and dental industries. Most recently, in 2010, he was founder, President, and Chief Executive Officer of Precision Dermatology, Inc, a privately-held dermatology therapeutics company that was recently acquired by Valeant Pharmaceuticals International, Inc.

Paul N. Clark, Chairman of the BIOLASE Board of Directors, noted that Nugent has already had a positive impact on BIOLASE during his brief tenure as Acting Chief Executive Officer, establishing a Global Commercialization Team and choosing new leaders of the sales and marketing divisions.

“Jeff brings considerable experience in the global medical device and dental fields to BIOLASE, and has a proven track record of results-based leadership,” said Clark. “His expertise in global commercialization, driving clinical excellence, and his disciplined approach to operations is what we need at this critical time for BIOLASE. With our established product pipeline, dominant position in the medical laser marketplace, and talented and loyal employee base, we are very pleased to have an executive of Jeff’s stature to lead the team.”

Previously, Nugent was Chairman and Chief Executive Officer of Ascension Orthopedics, a maker of joint replacement implants, President and Chief Executive Officer of Revlon Inc., and Worldwide President and Chief Executive Officer of Neutrogena Corporation. He also spent more than 20 years in leadership roles at Johnson & Johnson in research and development, marketing and general management, and was responsible for that company’s dental business.

“I had been aware of BIOLASE and its potential for sometime before joining the Company,” Nugent said. “I have accepted the permanent President and CEO roles because building successful companies and finishing what I start is part of my DNA. Also, I believe that there is great value in BIOLASE and I’m excited to lead the team and expand BIOLASE’s global leadership in dental lasers.”

Nugent has a Bachelor’s Degree in mathematics from St. Joseph’s College and an MBA in marketing and finance from Loyola University in Chicago.

About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical device company that develops, manufactures, and markets innovative lasers in dentistry and medicine and also markets and distributes high-end 2D and 3D digital imaging equipment, CAD/CAM intraoral scanners, and in-office milling machines and 3D printers. BIOLASE’s products are focused on technologies that advance the practice of dentistry and medicine and offer benefits and value to healthcare professionals and their patients. The Company’s proprietary laser products incorporate approximately 300 patented and patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 26,000 laser systems. Laser products under development address the Company’s core dental market and other adjacent medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Pinterest at www.pinterest.com/biolase, LinkedIn at www.linkedin.com/company/biolase, Google+ at www.google.com/+BIOLASEIrvine, Instagram at www.instagram.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.

BIOLASE® and WaterLase® are registered trademarks of BIOLASE, Inc.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Statements contained in this press release that refer to BIOLASE’s estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements in this press release concerning prospects related to BIOLASE’s strategic initiatives and anticipated financial performance. Forward-looking statements can also be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current perspective of existing trends and information and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors affecting BIOLASE’s business. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that may be detailed, from time-to-time, in BIOLASE’s reports filed with the SEC. BIOLASE does not undertake any responsibility to revise or update any forward-looking statements contained herein.

For further information, please contact:
Rene Caron
Allen & Caron
949-474-4300
rene@allencaron.com

EX-99.2 3 exhibit2.htm EX-99.2 EX-99.2

NEWS RELEASE

BIOLASE NAMES ALEXANDER K. ARROW, M.D. CHIEF MEDICAL OFFICER

Dr. Arrow to be Responsible for Clinical Research and Development,
Regulatory and Quality Affairs

IRVINE, CA (September 2, 2014) — BIOLASE, Inc. (NASDAQ:BIOL), the world’s leading manufacturer and distributor of dental lasers, today announced that Alexander K. Arrow, M.D. has been named to the newly-created position of Chief Medical Officer, effective immediately. Dr. Arrow had been the Company’s President and Chief Operating Officer since 2013 and was a member of the Board of Directors from 2010 to 2014. In a separate announcement to be made later this morning, the Company will announce the appointment of its permanent President and Chief Executive Officer.

Prior to coming to BIOLASE, from 2012 to 2013, Dr. Arrow was Chief Medical and Strategic Officer of Circuit Therapeutics Inc., a privately-held neurological device company. From 2007 to 2012, Dr. Arrow was the Chief Financial Officer and Medical Director of Arstasis Inc., a cardiology device manufacturer.

Dr. Arrow will lead the Company’s clinical development programs, continue to run the Regulatory/Quality Affairs, Clinical Education & Research departments, and work directly with BIOLASE’s new Dental Professional Advisory Board, noted Chief Executive Officer Jeffrey M. Nugent. He also noted that Dr. Arrow will continue to be active in the Company’s investor relations programs.

“Alex is an important member of our leadership team and we believe he will bring great value working directly with clinicians, given his knowledge of BIOLASE and our industry and his extensive medical training and background,” Nugent said. “Additionally, Alex will play an important role in broadening our technology and product portfolio and furthering our results in clinical development. I can think of no one better than Alex to lead our effort to recruit clinical investigators and manage all the stakeholders needed to create the clinical trial lineup we want.”

Dr. Arrow said, “I have been honored to serve as a board member and as President and Chief Operating Officer of BIOLASE over these last four years. With Jeff as our CEO, the most effective use of my time will be to ensure that our Regulatory and R&D programs, the Advisory Board, and external clinical investigators are all working to ensure the timeliness of research studies, and our new products and indications.”

From 2002 to 2007, Dr. Arrow headed medical technology equity research at Lazard, a global investment bank, where he provided research coverage on BIOLASE, among other companies.

Dr. Arrow graduated magna cum laude from Cornell University with a Bachelor’s of Science degree in biophysics. He also has a medical doctorate degree from Harvard Medical School.

About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical device company that develops, manufactures, and markets innovative lasers in dentistry and medicine and also markets and distributes high-end 2D and 3D digital imaging equipment, CAD/CAM intraoral scanners, and in-office milling machines and 3D printers. BIOLASE’s products are focused on technologies that advance the practice of dentistry and medicine and offer benefits and value to healthcare professionals and their patients. The Company’s proprietary laser products incorporate approximately 300 patented and patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 26,000 laser systems. Laser products under development address the Company’s core dental market and other adjacent medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Pinterest at www.pinterest.com/biolase, LinkedIn at www.linkedin.com/company/biolase, Google+ at www.google.com/+BIOLASEIrvine, Instagram at www.instagram.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.

BIOLASE® and WaterLase® are registered trademarks of BIOLASE, Inc.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Statements contained in this press release that refer to BIOLASE’s estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements in this press release concerning prospects related to BIOLASE’s strategic initiatives and anticipated financial performance. Forward-looking statements can also be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current perspective of existing trends and information and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors affecting BIOLASE’s business. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that may be detailed, from time-to-time, in BIOLASE’s reports filed with the SEC. BIOLASE does not undertake any responsibility to revise or update any forward-looking statements contained herein.

For further information, please contact:
Rene Caron
Allen & Caron
949-474-4300
rene@allencaron.com

GRAPHIC 4 e40332-142451719158472092_1.jpg GRAPHIC begin 644 e40332-142451719158472092_1.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_ MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"``S`,@#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#P[_AJ']IG M_HXCX[_^'<\?_P#R_KLM,^+?[;>M^%M5\U,JW:W"F!X#(L MRE"PK_6/Q3SK*O#KA'$<44>%LGS5X;'9;AIX*>$PN']K2QF+I8>IR5HX6LX5 M8QES4KTIQ,Q>+]C6R[ M`SQ5)5,/4QE!5*,YTU&JE6IR4&W&2:1^(_[/_P#P5(_;.^`GB'3+^/XQ>+OB M9X7M[B$ZGX(^*NNZIXWTK4;!2!+:6>HZ]^"/@3XT^$4DMM/\`%^EB:]TF:02W.AZW:.;76=&N9$X> M2POHY4CE`7S[$?^$^\8?\(LUD2+ M1O#G_"1:C_89M-X#?9FTP6I@WJK>44W*#Q7]CW_!#K1M8TK]A/P_-JGGQV^L M?$#QUJ>CP3*5`TY]0@@%Q` M39U/-<#@ZOU3#4L%/'8;,,'B<1.CC*%&,*=7$X65&$HUIQ=:$8U:;FXN,5_2 M_P!#/Q$XUQ/'V=^'^:9[C^(>'J>29CCZ/UW%U\PIY=B\LQV!PM.OE^)Q,ZE2 MC@\9#$U82P\)^PJ2=&M&FIJ MC_@@9\3OB3\2-"_:8D^(GQ"\<^/)-)U?X7II3^-/%NO>*7TQ+NS\;-=KI[ZY M?WS68NFMX&N!;^4LQ@A,N\QIC^;#]I#_`).)^/O_`&6OXJ?^ISKM?T+?\&[\ MB0^'/VK)96"11ZK\*Y9')X1(]/\`'C,S9Z`*,GV'3-?=>..4Y9A_`C,L3A\N MP-'$?4>$W&M1P>'IUDZF;9+&;56%-5+S3E&7O>\I-.]W?\T^C?G>;XKZ2N3X M;%9MF5?"O,>-E+#U\?BJN'<:>1Y\X)TJE65.T'",HWC[KBFK.*/H?_@JY_P5 M$U?]EVZB^`WP,ELG^,NJZ1!JGBCQ7=017UK\.M+U)"VFVUI8SHUO>>*-3M3] MOB-TLEGI=C)9W,L-W-=+#!_*3\1/C9\9OC'JMSJ?Q-^)_P`0?B)J5X\CR-XI M\4ZYKJ`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`^*-`OXC*1%)GA$;AD65PI(9U;RO%WA'ACQ M'\)9^(&791A\%G5/A["<4X'&T:-&GC?JKP]'&XW+QX$\=<9>$GCG#PNS7/L5F/#U;BK&\%9GEU>O7K9=]=6+JY?E MV<971Q$Y_4)SQT<-5E*ER>VP5:I3KQE+VG[1'[0/AW]L_]IK0?#_Q MR^,>A:'I/QB\:6.E:-HOQ-\:Z7I6FV-OJLR06>GZ=8ZW#:6=I`@"PP6\$4,: MX5%`&!^E/_!!GXN?%GXC?&KXYZ?\0?B;\1?'=CI_PMT>\T^R\9^-?$GBBTL; MN3Q99P/=6=MK>I7L-M>!$D:(M&SE6Q7XZ_\%"@1^W+^U5GK_PNSQUQ M]=8FQ^G7WK]3/^#>;_DO'Q__`.R1Z+_ZF5E7H>(N5992^COB\52R_`T\0N#> M&9JO3P>'A64YRR7GFJRI*ISSO+GDI7DY2NW=W\OPFSK.*WTJ\!@ZN;9G6PC\ M0.+Z;PU3'XJ>'=.$<^Y*;H2JNER0Y(\L.7ECRQLO=1_6*F<'/J>V*^9OVN_V MF_!_[(WP-\6_&CQA%)J*:,D&G^'/#MO/';W?BCQ5J>^+1]#MY9,K"DTB2W5_ M<[7:TTRTO;E(II(D@E^G*_FZ_P"#AOQ7>V_@K]GOP3#-<1V.H^(_%GB*]B7` MM[F2QL+*QL_-Q)N>2`W,YB!CPHF=@^25K^%O"KA3"\:\?\,\-XYS6`QV.E/' M*$G"=3!8+#UL=B*$9Q]Z#Q%+#2H>TBU*G[3GBU**9_I5XU\;8SP[\+N+^+LM M4'F>6Y="GEDJL%4ITLPS'%X?+<)B)TY)PJQPM;%QQ3I33A5]C[.2<9,_$7]H MS_@HE^UA^TOKNHWGB_XK^*?#WA:ZFE-C\._`^MZIX8\&V%HV1%;3Z;I5W;-K MLL:85K[79-0N2[.8S!&XA7P#5O"?[0'PSL-'^(&N>&OC%\/M+\5R07OA_P`; M:KHWC3PI8>)95C^T6UWH_B2\M["WUB00_OX+BRO+EA'B1'VG=47[/^@67BOX M\?!3PQJ<23Z;XD^+?PWT'4898UFBEL=9\8Z-IUW%+$QVRQR6]S(LD9.'4E20 M"2/[-?\`@LKI.F7G_!.?XYS7-A:R2Z!??"34=&9HD)TR]?XQ^`-$:XLSM_<2 MG2=6U+3]T>T_9;VXA'[N1EK_`$$XJXSR;PPXE\..`)PV69GG&*HSQ%;%PE@**P^`6&PRPM)QI MSQ"<5&E0]C4_G_\`V&_^"NW[07P-\<^&?"_QK\:^(OC!\&-3U*TTO7$\8W]S MX@\8>%+*[GCMSK6@>)=0DFU>]330_GR:+JE[=VMQ;QM!9O8OL<_TG_MX_MS> M#OV._P!G^T^*5FMIXK\6>/\`R=,^$>@B5EMO$.H7NGC4_P"W;QE*W">&M'TR M2&^U"XC0N\UYI>FCRIM3BD3^"1ONG_/>OU3_`."B_CWQ%XR^#O\`P3P;4I[R MXT9?V5[;4+.2XWA6UA_%>J>']2PAD>,2IIGAK08V9?WAA2#>=NQ5^<\1/!#@ M_/?$+@''PR[#Y=@\SQ^9T>(\'@(0P=#-8Y?EM;-<(I4J'LX4Z]>IA:M#&5J, M85J^&J2ES>UIJHOK?"GZ1G'W#?A7XGY95S;%YMF&399DU?A+,,SJ3Q^)R26: MYOALCQ[5;$NI4JT,+2QE'%9?0KRJ4,/C*:BH.C5E2?R9\=OVT?VG?VC==OM7 M^*'Q>\:ZG97%-,N+;2(_*&Q3=RVL^H7`CC: M\N[AT5AYK\,?CS\:O@IK-MKOPI^*7CSX?ZI9R*RMX:\2ZMIEM.J2M*;;4=-B MN1INIV3R.YGT_4K2YLY_,<3P2!F!^I_^"86H_!JQ_;7^#S?'2ST&]\#WESK^ MF0+XJM+:]\-Q>*]1T#4+7PE-K-K>)+:26O\`;DEI#"]W&UK!>RVMS=;;>"5A M^Q7_``4F_P""27Q4^.G[0%A\1OV6/!'PTT#P;JW@'0X?%5F=@N[RRT6UL/LRP7/AY?#CRW4*HMQ>?:78&3>S?99WQMP'P3Q+@/#G.LDRO( M>'K15"I5]G2]I4DY-IU:$)TFJJJ+\_X= M\.O$SQ%X0S/Q9X?XBSGB;BK+.*J>48C)\#7S3'\71A6PU#%K.HXJC7EB*5#V MM94Z<5&*:H8BI"M%T72/LC_@E%_P4:U']LGPQX@^''Q12SM?C?\`#C2[35[W M4+*&*TL?'GA2>Y73G\0V^GP@)8ZGI-_)9VFO6T*I:E]5TVZLD5)KF*V^&_\` M@JO_`,%6_B_\-OC#XA_9P_9NUY/!2^!H[*P\>?$.TM+2]U^^\1WUC%?WFA:` M^HV]S;:59Z+!=P6-]?);-?R:M%>K:SP0VT,TVQ_P3._X)B_M=_LI_M5^&OBM M\2;/P58>`H/#/C+0O$1T#QK;:O?W(U?0KF+2H/[/BM(6N(5UI-/G<[P(O*$I MSLK\`_VN]7O/$7[4O[0NN7SL]WJ?QB^(-W.6=G.^3Q-J.5#-SA``JYZ*H`&` M!7X[P/X<^%^=^-'$F/R!9+Q%PM@>'L!G.#RW#3HYADV"SO,L94PE:@Z-YT:E M/#PP-?%4<'44Z.'^OTN2FE0H*'[[XC^+'C-PY]'OA++.)WQ#PIQKF7%.99!C M\VQ=/$97G^8\.Y/@*&,H8GV]J6)I5<7/,<-@\1CZ,J>)Q/\`9E=SJRGB,3*= MZ3]J?]L3Q]KD42?M"_M&^*O$%^WD6EE8_%'XD:C?SY>25;33M-L-:D98E>25 MX[.RMEBC,DC)$H9Z]3"?\%-"`5C_`&[2",@@?M`$$'OPO(([@U^I/_!O1X)T M#4O'W[0/CR]T^UNO$'ACP[X/T+1+R>&.6;3K;Q%?:Q\/YA3RJA@? M;XK$JCAE*KC,'A\=&E0P]#+Y*G2I4J]*+FZLN>?/:-.,5S8>#'T;LW\5>!,N MX[SGQ4XIRRIG6)S%8;!8.6)Q M524KQ_E.^._PO^/7B/4OV3O$OQ*\'?%OQ@UG\`?V:A9VEUX7\9^*_$%]*GPY M\#P?$/PWX?EBT36+[P=\`?S M[=\?R[>WT]2OP"/CICEA,%A%P_2HPP=.I2@L%FV.P%%PG6E47[C"TZ:4ES-S ME4E5E.I*"?A]XD^''@_XA>, M?#'PY\77OG>*?#NAZI>:9HVO79MA;;-5%JT8NB;0&)H)92K0EU965FSY0>A^ ME?U3?\$)/A_X(^(?[,/QY\.^._"7AWQ?H>K?$.TT[4=*\1:-8:M9W=E<^&DC MEMI8;V"5?+8'/&&#?.I#@&O]`/%7B_`<#<)5>(\RR6GG^%P>8Y9"6`G*C!J= M?&4J<,52E7H8FG[?"R:K44X0;G!)5J3:J0_RZ\%.!,S\2>.L/PEE'$-7AC&X M_*LYJ0S.G#$5$Z>&P%6M5P5:.&Q.$J_5L;"+P^(:J32I5&W0KI>SE_-1\$]* M^$6M?$WPIIWQT\4^*_!OPPGU.W'BG7?!OA^U\1ZY;V"R*TL4%K=:C8BSCN5! M@DU6&WUJ?3ED^UQZ%JGEFU;_`$(OV>;/X0Z=\&/AWI_P%GT:Y^$5EX9T^V\$ M3Z%="]LI-(2,%)&N2S337LLC22ZB]T?M;7SSM=`3EQ7\&'[;'P2TK]GC]JCX MT_"'0(Y8O#7A3Q?<'PS'//);BX=[B M8VADFDDD9I'_`'-_X-]_CUKUZ_Q@_9TUC4+B\T;1]-L?B5X-@N)))8]+6;4( M=$\3V=L&RMM:S7-WHUXL2,%>ZN+J39DEJ_#OI(<-5>-/#S+/$#*>*V<^%^>Y'EL%W%/(\-_$:3>9$GY;>JL?G/T=7*/TD,$XI\T<1X@M;WNN'>(VM%KO M;]-3^<36;[^T]8U?4O,,O]H:IJ%]YK+L:3[7=S3^84P-I?S-Q7`P3@@=*_J\ M_P"#>BSMU_9W^.M\L8%WUM)I>27@L_`_A^:VC()*XBDOKM@0`%*P^DXE'P@S2,'[BS#(HJS5G&.8X=Q3MHU[L7II=)K9'1]#ENIX\Y M+.HKU/[)XFF^9:QG+*Z_,_>NT_>DGULVGNS\R_\`@O1!#%^W%I+QQJCS_`SP M#+.RJ`99!XA\`;CCHK=*^I/^"]O_)\.B?]D(\!?^I-X]KY&_X) MB0S3?M[?LQ^3$TOD_$6*>7:,[(8M'U5I)&]%08+'L.:Z^%XQG]'"A&IK!^&. M8I\SZ+),7;7I:RMT6B1Q<92E3^EMB94KJ2\8LFM97?O9_E_-IW=VWW;;9RO_ M``4*'_&E5_>5'\S^F:GJ&C:EI^L:3>7.FZKI-[::CIFH6*6-70@J*]>\6?M'_'SQ[X?O_"?C7XP_$/Q5X9U4VAU+ M0==\4ZMJ6E7WV&^MM2L_M5G=7,D,WV74+.UO(-ZGR[FWAE7#QJ1+^S%;6]Y^ MTE^SW:7D$-U:7?QQ^$UM=6MQ$DUO<6\_CW0(IX)HI%:.6&:)GCEBD5DD1V5U M*G%?V!?\%=_AK\/=`_X)X_M!ZOH?@;PAH^JVA^$WV74M+\-Z/I]];_:/CC\- M+:;R+NULXIX?-MIIK>7RY%\R&62-LH[*?[HX]\1#P6"S6=7#4YY-4Q&;8#`1KTX5L'B*E1TZF)CB;4:V'DW224XR:E'_-?PP\) M\[XW\._%'B_+N,:^08'@?*,?C\QR6E0Q=2GG]+"9'F&:5,/4J4,?A*5-5J." MGA&Z^'Q<>6NY.#@G3G_$D_W3^'\Q7]'GQ_\`V/\`Q'^T!_P25_8]^+7P^TV7 M5_'7P*^'5U?ZCHEE"\VH:_\`#[6;V[;7UL8H\OO-/L=8M;14)ETY]<$ M.ZZ-O#-_.&_W3^'\Q7]]O_!,]%D_8'_9@1U5T;X96BNC*&5U;4M45E93P0P) M!!!!%?,?2-XJS#@G+N`>*,KY)8O*>-(UE1J-JEBJ%3)DDZV#Q5'B+),3@<= M13T=7!XVA0Q,82]RK[+V52]."6)]RL-T(IO$?[0O[*. MC)!KTWVO6?'OP=L8DCMM7G.)KO7?`4,2(EMJ$^)KG4O#KL8;NX9I]*:%I&LQ M_+K=VEU9W5U8WUO/97ME/+:W=I=0R6]S;7,$C13V]Q!*%EAFAD1HY8I%5XY% M964,I%>_A<3X<_2(X*=.K".(<5%U\/)TZ6>\,YG*&DZ=1*3IR3B_95X\^"Q] M*+A452'M:,/EL9A/%CZ*7B'&I2JSPW/*2PV*@JE;AOC#)Z=2/-3K4VU&K'E< M?;8:;IYAE5><:E*5*?L:]3_3!TG5],UO3-/UC1[^UU32=4LX+_3=2L9X[JRO MK*ZC6:VN;6XA+QS030NDD_^I-J5?MM M_P`$2?V\O$VB^-K/]C_XG:Y<:QX.\3K<3_!^_P!2F:>[\*>(XHGN;SPC#=2L MTK:!KT,;3Z78EBFEZO%,EH@BU:80?B3^TY_R<7\<_P#LK'C[_P!2;4J_./`/ MP^S3PU\1/$'AW,IQQ%)9/DN+RS,*<'"GF&6UL;CHT<0H-OV56,H5*&)H\TE2 MQ%&I&$ZE)TZL_P!:^DYXHY-XN^%/A9Q7E-.6$K//N(VHSA5HXG"8CEBZV%K4I3A2K>UHT^,\`_%[XH_"HZFWPV^('BSP,V ML"V&JGPOK=]HYU`6AE-J+O[%-$)_L_GS>5YF[R_-?;C<:]B\-?M=?M13^(_# M\,WQ^^+$L4VMZ5%)&_C;7&22.2_MU=&!NR"K*2I!&"#S7[.?\&^WA#PIXKN_ MVF!XH\,Z!XB%E;_#8V8US1]/U46IFD\6B8V_VZWG\GS1''YGE[=_EINSM%?T MKK\(?A2C*Z?#3P$KHP967PEH(964Y#*189#`X((Y!&1S3\3O'CAO@[C'.N&< M?X>8;/,7@:>!4\UJ8K`4YUWB\MPN+@W"ME.)JKV,*\:*O7E=4[QY4[17@W]& M?B[C_@'AWC'+/%7&<.8#,:F/E2R2E@\SJTL,L!F^+P511GA\\P=%_6*N$GB' MRX:G9UK2YY)R?<6)WVUJQ)+-;0,23DL6B4DG\3^=%650+TZ```=,<8[>,?&?B:/Q!HFL:CXB72/#FB MO!I0L(3J6GV^G7>IZKLG43-:VUYI8EC.P7T+#-?ZN>/'"V><9>'F.R#AW!?7 M\TQ68Y34IT/;X?#15*ACJ-2O5G6Q56C2C"E33G*\^9I6A&4FHO\`Q&^C1QIP MWX?^*V6\3\5YA_9F38+*<^IUL4L-B\7+VV)RVM1PU&%#!4,17G4KUI1IPM3Y M%*2=2<(7DO*_^"L6JV>J_P#!0#]H%K*3S4L=?L'_@W_TFYG_:Y^).MH#]CTWX`^(=-N&V$J+C6/'?P]N+ M4&3[J%DT:[(5N7"L5X1J_%7Q_P"./$GQ.\<^+/B%XLO#J7BCQMXBU7Q)K=V% MVB?5-9O9;VY\B(9\J!9)3#;0K\L-NL4*?*@K^MS_`((<_LF^(O@K\&O%GQF\ M?:/=Z)XK^-4VE#0]+U*W>VU"S\":$+F72;N:"4>;;G6[W4+N_C1O+>6S6R>2 M/`B8_)>+^+PO`O@)+AS&XFC/,*N09+PI@H*:OC,71I8*AC*E&+]]TJ6'P^)Q M#ERVA&-.,FI3A?[CP&P6.\2OI-PXMR[!UXY72XHXAXWS"HX2YMF&)P% M+$3BW!5JV*Q6#PL8<]YRE4G&,H4YG\K_`.T?_P`G%?'W_LM/Q2_]3K7J_H'_ M`.#?.Q_M3P1^U]IAP1J4WPVL#NZ#[9H_Q`M^<$$#]YR5/3WZ?S\_M(?\G%?' MW_LM?Q3_`/4YUVOZ&O\`@W7`.@_M4Y_Z#'PF_P#2'QW75XZR,\PXZA)=XRR'B&+7W/3Y;G\VWQ.T&;PM M\2/B!X:N(6@FT#QKXITAX7#J4_L_7+ZU48?Y\%8@5+$DJ023G-?T]?\`!O#K M\<_P;_:*\,K)&9=(^)OA77I(0K"5(O$?A:;3XI'<_(R2-X6F6-5^9&BE9QM= M*_*W_@L3^R_X@^`W[6'BKQS;:5-_"^LPV\@TR'6KD+_P`)1X"K8_!3K591ITJ] M+V6,PK565.,<5!0J3A'F:X_#?,\+X"?2-F^,UBA"=:OA:SKY?C8NA"K*>#G*I2A4ER)_3'_!=;64U3]N^_LD>- MF\.?"7X=Z/((PVZ-YO[;\0*DQ8!3(8]=C<%,KY3Q`_.'`\T_X(Y>%+CQ7^WO M\)F2-WB\-6?BKQ3/(%;RX4TO0;O8TKJ-J!Y)UC3>P#R,J`%B`?BS]I3X]^*O MVG?C;X^^-_C2WM++7?'.J0W;:;8-*]EI&G:=86ND:+H]I),3-+;Z9I-A8V*2 MR_O)A!YL@WNU?T(_\$"OV7_$&C6GQ$_:D\6Z/<:;IWB+3HO`/PPDOHFBDUBQ MCNEOO%OB*RCDVN-/2XMM.T33[Y5:&^F76X8W7[$WF&OT>IY3FE>C3S M*AP=A.&%3C4C)5\YS'!1P->EA7?]^J,ZN)Q#<%KAL-5JOEA%M=W`5%^+WTJ: M>>Y-0Q%;*<1X@8WC&56=*<'A\@RC,'F.&KXQ6_V9UZ=#!X5*H[+%XJEAUS3F MK_B1_P`%"R/^&Y?VJ@._QL\G^+]% MUB.!A8V_B:WTJRTOQ=H=Q<*H0:@-4L7UY48!I++6X"IE>"Y9?DO]AC]LKQ-^ MQ+\9A\4=%\-VGC/2]2T:Y\.>*?"MU?OI)U;1[B>&Y4V6JI;7W]GZA:W$*36L M\EC>0`[DDMI%8;>_'X&KXB?1]HY=PS*CC,9FW!N34,'2]M3I*>.R^GE\L1@9 MU9RC2I8B&(P=;"3=2<(4ZZ_>3A!.2\S+,PH>%'TI,1FO&$<1@,!D?B#G^(Q] M?ZO6JRAEN:5,QAAQIU*M7#2O3A.HU%_Z""YQR<^G MTK^8[_@XB^_^S=_US\;?^AZ57J-I_P`'#OP9-O$UY^SM\4(;IE!GBMO$_A6Z M@C<]5CN)5M'E7&,.UM"3GE!W_-O_`(*B?MJ>$_VW_A]\#_B+X2\&>(O!-CX> M\2>./#$VG>([S3;V[N)TM-%O3E?S7X+>%/B%PAXF\ M,9SQ'PSBLLRRE5S*A4Q=7$Y?5IQK5\FS"%&%L-C*\WSRT3C!QZMVU/Z[^D-X MW^%?'G@YQCD'"?&&"SC.*]')\32P-'!YK0J2H8;/\IJ5ZG-C,!AJ25.#YI1E M-3W48MIH_-S]EK_DYK]G3_LO'P@_]6!H%?V8_P#!8[_E'!^T7]?A!_ZOCX7U M_&=^RU_R4_P#K59*?COT:?^4?_I,_]DKGO_K%<0'\+C?=/^>]?VO?L4?M?_LT M?`/]BS]E/PG\9/C+X-^'OB._^#^G:U9:1XAN[FWO+G2Y]:UFVBOHTAM9U,#S MVUQ$IW@[XG&.,U_%"WW3^'3ZBOUR_;4^`7B:X_8A_8!_:0T;3+F^\,6OP7C^ M&7C.[MHFFCT+4(O$>NZWX8O=0"JWDVNLQW^J:?%=<017.F06\[QSWUHL_P"H M>-7"F2<;_P"HW#&?9EBLJPF:<38FG0Q.$GAX5I8ZED.:U\-AT\52K4E]8=.5 M*"Y'*I5E"E#WY13_`!SZ//&_$?AR_$CC+AC*,%G6.R;@_"5,5@\?#%5*$,MK M<3Y'A\9BW#!5J%=K"QJQK3DI\E.C&K5J?NZH6U_>V7AW0[VYGU*YM=,M7O+^>*.6TA0I:VL`OVF/`MC:Z(WQ6UO4_"OQ&TBT2.&TO/%]GIPU?2?$]K;Q M@".[UK3;;5H-=*JJ2WFGV=Z=US?73M^*W[-OQ_\`&G[+_P`9_!?QM\`1Z?<> M)/!MU>21V&JI-)I>JZ?JFGW6DZMI5^EO+!+]EOM-O;FW=HI8Y86=9X762)&7 MZD_;M_X*1_%7]NJW\&Z'XJ\,>&_`O@SP1>W>L:;X;\.2WMX;W7KZT%C)JVJ: MCJ,C33RV]H9[:P@@BMX+>&ZN2R2RRM+7YQPAX$\0^&OBID.;\)9GB,5P=/+L M12XBQ&98O"PQRKTZLZM2"IQC/]9X[^ MDMPKXO>"O$N1\=9/A,%Q_3S;"5N%,+E&`QM3!4HTJN`G',H9AB\1B/JE:-*6 M:X3'4I5HNOA*M*G2I5'5G*G\R_LK:UJ7A[]I;X$:SI/G_P!HV?Q7\#-;_96V MSYFU^QMY/+;(`(AFDSS]W(SSS'^TX"/VC/CH""#_`,+8\>Y!X/\`R,VI=#OAEJ]K\0O'.JM!(VGZ?I^ARFXTVRGN`I MCCO-8U1+6SL(23))(7EV^3!,\>M_P5H_9N\5_`7]L+XDZY=Z;!M>2*4:;=KXAF-[X@T/[00T46I>']=EO[26S:5ISIITS42BQ7\:C]I7%& M21\6EPR\5065P M=Q'/P,EQ@L'B7D%/Q$6%57V4O9PY\CCAZF/OLL+/%QHY=+$O]T\9&GA^=5;0 M?Z2?\&[-U;IJO[3MFTJ_:IK#X;W,,& M\Z"S\5^%;^VC(=@OE7<\&G2S!H]C,7LH-KL\:AP@D?\`E/QX\%_$+B+Q$S3B M3AS(JF%&2\)<6\34^'\YR+%9O"=#%X#-*M+$X;'9KBLRH8G#X MG!X+%8>2MC70G2G4A7A.C.3I.FXU)_T345\N?L??M0^'_P!L'X*Z1\;?#'AG M6O".D:OK.O:-%HNO7-C=ZA#+H-\;*:9YM/9K9HYG&^,*2RK\K45_)&9Y;CLF MS'&Y3F>'EA,PR[$UL'C<+.4)3P^)P\W3K4I2I2G3 MBGH?YY&Q?3]3_C2,H"G`].Y]:**_VQ:5GIT?Y?\``7W'_.TMUZH_JN_X)1_L M;?LR>)O#EC\3?$WPA\/>)?&NFS^=8:IXBNM0O!%W#%7*\JRW+:N89?3Q&/J8#`X7!U,;B-O;XN>'I4Y8FM9M M>UK.<[-KFU/\Y3]I``_M%?'W/;XU?%/U_P"AYUZOZ&?^#=D`:!^U3C_H,_"; M];'QX?YT45_7&JKYD\TLKXR[LV3117Y-]#[%XJ;XPP4\3B)8.BLLK MT<)*M4EAJ5>M/$1JUJ=!R=*%6K&G3C4J1@ISC""DVHJW[A]/7`8&G_J!F,,' MA(9AB*F<86OCH8>C'&5\-0A@9T+O"EQ#?7UQHE[=ZE:6ES<6*QS6WVG^S+V MQFN(%D&9+2:5[2X7,=Q#+&2I_O+T#0]&\,Z-I7A[P]I=CHNAZ/9PZ=I6D:9; M16>GZ?8VL2QV]K:6L"I###"@"HB*`!117QWTM\7BY\;Y-@I8K$2P='(%A MF%?BC$X6OCHX>C'&5L-0P6"J4,/5Q2@J]2A1G5JSI4IS=.G.I.4(ISDWY[\; M?A%\-/C3X`U?P5\5/!>A^-_#%S!+,^E:W:F5(;A$(CNK*YA>&]T^\CR?+O+" MYMKJ//R2K7\(G[;7PK\!?"/XS:UX4^'F@_\`"/:!:7^K0V^GC4]9U41QVUXL M<"_:M;U'4KQO+1BN7N&9NK%C@T45Z7T2[%]/U/^-?07B``?LQ_#WV^* MOCK'_@C\.T45_=&;)>VR33_F2']H_1I_Y1_^DO\`]DCG3_\`-*XA/X7V4`$@?S]: M_O$_X)_^$/"_CW_@F_\`L]^#O&F@Z7XG\+:_\([>PUG0M9M(K[3=1M)=0U0M M#G3K4*W`M6E6HU81J4J MM*IGF40J4ZM.:<*E.<)2A.$TXRBW&2:;1_'?^W)\./!7PG_::^*'@;X?:''X M<\*:+K/EZ7H\-YJ-]#9QR(LC1Q3ZI>7UX8PS-L1[AUC7"1A4`4?-/A.PM-3\ M4^'=.OHO/LK_`%?3;6[A\R2/S8+BZCCE3S(7CE3>C$;HW1USE6!P:**_H'A7 M$5\1P1P_BJ]>M6Q5;AS+ZU7$U:DZE>K6GEU&AA*%&G2PU'#PSBM3A0I4*<8TJ=&-- M*G&E""A&"45%121_H(_L??!#X3_`[X(^$M%^%'@;1O!=AK>EV&MZW_9JW,]] MK.K3VJ"2_P!7U74;B]U74[@*/+B>^O9_(B_=0"./Y:]"^.GP8^%?QR\`ZKX. M^+?@70/'?APP2W46GZY:F4VEVL)"WFG7L#P:AIEXG&R[T^ZMKE<`K*"!117^ M2.89IF;XFQ>:O,<>\T6<5:ZS)XO$/'JM'%.,:RQGM/K'M8I)*I[3G222=D?[ MI97DN3K@_`9(LIRQ9-+(\-AGE"P&%65O#SPD'.@\![+ZHZ,FVY4G2Y)-MN+N MS^$K]M?X6^!/A)\9-;\*_#W0O^$?T&TU+4X+>P&IZQJHCBMQ8&%!I6Q&( MJ3K5ZLW!-SJ5:DI5)S;6LI2;?5G^$WB)A<-@N.N)L)@L-0PF%P^<8JE0PV%H MT\/AZ-.-2T:=*C2C"G3A%:1A",8I;(_ME_X(A\?L#^"?^QZ^(W_I^8_SHHHK C_*WQ9_Y.;QY_V56=?^IU4_VN\#?^3.>&/_9#\-_^JO#G_]D_ ` end GRAPHIC 5 e40332-1424517203674a9fb0_1.jpg GRAPHIC begin 644 e40332-1424517203674a9fb0_1.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_ MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"``S`,@#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#P[_AJ']IG M_HXCX[_^'<\?_P#R_KLM,^+?[;>M^%M5\U,JW:W"F!X#(L MRE"PK_6/Q3SK*O#KA'$<44>%LGS5X;'9;AIX*>$PN']K2QF+I8>IR5HX6LX5 M8QES4KTIQ,Q>+]C6R[ M`SQ5)5,/4QE!5*,YTU&JE6IR4&W&2:1^(_[/_P#P5(_;.^`GB'3+^/XQ>+OB M9X7M[B$ZGX(^*NNZIXWTK4;!2!+:6>HZ]^"/@3XT^$4DMM/\`%^EB:]TF:02W.AZW:.;76=&N9$X> M2POHY4CE`7S[$?^$^\8?\(LUD2+ M1O#G_"1:C_89M-X#?9FTP6I@WJK>44W*#Q7]CW_!#K1M8TK]A/P_-JGGQV^L M?$#QUJ>CP3*5`TY]0@@%Q` M39U/-<#@ZOU3#4L%/'8;,,'B<1.CC*%&,*=7$X65&$HUIQ=:$8U:;FXN,5_2 M_P!#/Q$XUQ/'V=^'^:9[C^(>'J>29CCZ/UW%U\PIY=B\LQV!PM.OE^)Q,ZE2 MC@\9#$U82P\)^PJ2=&M&FIJ MC_@@9\3OB3\2-"_:8D^(GQ"\<^/)-)U?X7II3^-/%NO>*7TQ+NS\;-=KI[ZY M?WS68NFMX&N!;^4LQ@A,N\QIC^;#]I#_`).)^/O_`&6OXJ?^ISKM?T+?\&[\ MB0^'/VK)96"11ZK\*Y9')X1(]/\`'C,S9Z`*,GV'3-?=>..4Y9A_`C,L3A\N MP-'$?4>$W&M1P>'IUDZF;9+&;56%-5+S3E&7O>\I-.]W?\T^C?G>;XKZ2N3X M;%9MF5?"O,>-E+#U\?BJN'<:>1Y\X)TJE65.T'",HWC[KBFK.*/H?_@JY_P5 M$U?]EVZB^`WP,ELG^,NJZ1!JGBCQ7=017UK\.M+U)"VFVUI8SHUO>>*-3M3] MOB-TLEGI=C)9W,L-W-=+#!_*3\1/C9\9OC'JMSJ?Q-^)_P`0?B)J5X\CR-XI M\4ZYKJ`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`^*-`OXC*1%)GA$;AD65PI(9U;RO%WA'ACQ M'\)9^(&791A\%G5/A["<4X'&T:-&GC?JKP]'&XW+QX$\=<9>$GCG#PNS7/L5F/#U;BK&\%9GEU>O7K9=]=6+JY?E MV<971Q$Y_4)SQT<-5E*ER>VP5:I3KQE+VG[1'[0/AW]L_]IK0?#_Q MR^,>A:'I/QB\:6.E:-HOQ-\:Z7I6FV-OJLR06>GZ=8ZW#:6=I`@"PP6\$4,: MX5%`&!^E/_!!GXN?%GXC?&KXYZ?\0?B;\1?'=CI_PMT>\T^R\9^-?$GBBTL; MN3Q99P/=6=MK>I7L-M>!$D:(M&SE6Q7XZ_\%"@1^W+^U5GK_PNSQUQ M]=8FQ^G7WK]3/^#>;_DO'Q__`.R1Z+_ZF5E7H>(N5992^COB\52R_`T\0N#> M&9JO3P>'A64YRR7GFJRI*ISSO+GDI7DY2NW=W\OPFSK.*WTJ\!@ZN;9G6PC\ M0.+Z;PU3'XJ>'=.$<^Y*;H2JNER0Y(\L.7ECRQLO=1_6*F<'/J>V*^9OVN_V MF_!_[(WP-\6_&CQA%)J*:,D&G^'/#MO/';W?BCQ5J>^+1]#MY9,K"DTB2W5_ M<[7:TTRTO;E(II(D@E^G*_FZ_P"#AOQ7>V_@K]GOP3#-<1V.H^(_%GB*]B7` MM[F2QL+*QL_-Q)N>2`W,YB!CPHF=@^25K^%O"KA3"\:\?\,\-XYS6`QV.E/' M*$G"=3!8+#UL=B*$9Q]Z#Q%+#2H>TBU*G[3GBU**9_I5XU\;8SP[\+N+^+LM M4'F>6Y="GEDJL%4ITLPS'%X?+<)B)TY)PJQPM;%QQ3I33A5]C[.2<9,_$7]H MS_@HE^UA^TOKNHWGB_XK^*?#WA:ZFE-C\._`^MZIX8\&V%HV1%;3Z;I5W;-K MLL:85K[79-0N2[.8S!&XA7P#5O"?[0'PSL-'^(&N>&OC%\/M+\5R07OA_P`; M:KHWC3PI8>)95C^T6UWH_B2\M["WUB00_OX+BRO+EA'B1'VG=47[/^@67BOX M\?!3PQJ<23Z;XD^+?PWT'4898UFBEL=9\8Z-IUW%+$QVRQR6]S(LD9.'4E20 M"2/[-?\`@LKI.F7G_!.?XYS7-A:R2Z!??"34=&9HD)TR]?XQ^`-$:XLSM_<2 MG2=6U+3]T>T_9;VXA'[N1EK_`$$XJXSR;PPXE\..`)PV69GG&*HSQ%;%PE@**P^`6&PRPM)QI MSQ"<5&E0]C4_G_\`V&_^"NW[07P-\<^&?"_QK\:^(OC!\&-3U*TTO7$\8W]S MX@\8>%+*[GCMSK6@>)=0DFU>]330_GR:+JE[=VMQ;QM!9O8OL<_TG_MX_MS> M#OV._P!G^T^*5FMIXK\6>/\`R=,^$>@B5EMO$.H7NGC4_P"W;QE*W">&M'TR M2&^U"XC0N\UYI>FCRIM3BD3^"1ONG_/>OU3_`."B_CWQ%XR^#O\`P3P;4I[R MXT9?V5[;4+.2XWA6UA_%>J>']2PAD>,2IIGAK08V9?WAA2#>=NQ5^<\1/!#@ M_/?$+@''PR[#Y=@\SQ^9T>(\'@(0P=#-8Y?EM;-<(I4J'LX4Z]>IA:M#&5J, M85J^&J2ES>UIJHOK?"GZ1G'W#?A7XGY95S;%YMF&399DU?A+,,SJ3Q^)R26: MYOALCQ[5;$NI4JT,+2QE'%9?0KRJ4,/C*:BH.C5E2?R9\=OVT?VG?VC==OM7 M^*'Q>\:ZG97%-,N+;2(_*&Q3=RVL^H7`CC: M\N[AT5AYK\,?CS\:O@IK-MKOPI^*7CSX?ZI9R*RMX:\2ZMIEM.J2M*;;4=-B MN1INIV3R.YGT_4K2YLY_,<3P2!F!^I_^"86H_!JQ_;7^#S?'2ST&]\#WESK^ MF0+XJM+:]\-Q>*]1T#4+7PE-K-K>)+:26O\`;DEI#"]W&UK!>RVMS=;;>"5A M^Q7_``4F_P""27Q4^.G[0%A\1OV6/!'PTT#P;JW@'0X?%5F=@N[RRT6UL/LRP7/AY?#CRW4*HMQ>?:78&3>S?99WQMP'P3Q+@/#G.LDRO( M>'K15"I5]G2]I4DY-IU:$)TFJJJ+\_X= M\.O$SQ%X0S/Q9X?XBSGB;BK+.*J>48C)\#7S3'\71A6PU#%K.HXJC7EB*5#V MM94Z<5&*:H8BI"M%T72/LC_@E%_P4:U']LGPQX@^''Q12SM?C?\`#C2[35[W M4+*&*TL?'GA2>Y73G\0V^GP@)8ZGI-_)9VFO6T*I:E]5TVZLD5)KF*V^&_\` M@JO_`,%6_B_\-OC#XA_9P_9NUY/!2^!H[*P\>?$.TM+2]U^^\1WUC%?WFA:` M^HV]S;:59Z+!=P6-]?);-?R:M%>K:SP0VT,TVQ_P3._X)B_M=_LI_M5^&OBM M\2;/P58>`H/#/C+0O$1T#QK;:O?W(U?0KF+2H/[/BM(6N(5UI-/G<[P(O*$I MSLK\`_VN]7O/$7[4O[0NN7SL]WJ?QB^(-W.6=G.^3Q-J.5#-SA``JYZ*H`&` M!7X[P/X<^%^=^-'$F/R!9+Q%PM@>'L!G.#RW#3HYADV"SO,L94PE:@Z-YT:E M/#PP-?%4<'44Z.'^OTN2FE0H*'[[XC^+'C-PY]'OA++.)WQ#PIQKF7%.99!C M\VQ=/$97G^8\.Y/@*&,H8GV]J6)I5<7/,<-@\1CZ,J>)Q/\`9E=SJRGB,3*= MZ3]J?]L3Q]KD42?M"_M&^*O$%^WD6EE8_%'XD:C?SY>25;33M-L-:D98E>25 MX[.RMEBC,DC)$H9Z]3"?\%-"`5C_`&[2",@@?M`$$'OPO(([@U^I/_!O1X)T M#4O'W[0/CR]T^UNO$'ACP[X/T+1+R>&.6;3K;Q%?:Q\/YA3RJA@? M;XK$JCAE*KC,'A\=&E0P]#+Y*G2I4J]*+FZLN>?/:-.,5S8>#'T;LW\5>!,N MX[SGQ4XIRRIG6)S%8;!8.6)Q M524KQ_E.^._PO^/7B/4OV3O$OQ*\'?%OQ@UG\`?V:A9VEUX7\9^*_$%]*GPY M\#P?$/PWX?EBT36+[P=\`?S M[=\?R[>WT]2OP"/CICEA,%A%P_2HPP=.I2@L%FV.P%%PG6E47[C"TZ:4ES-S ME4E5E.I*"?A]XD^''@_XA>, M?#'PY\77OG>*?#NAZI>:9HVO79MA;;-5%JT8NB;0&)H)92K0EU965FSY0>A^ ME?U3?\$)/A_X(^(?[,/QY\.^._"7AWQ?H>K?$.TT[4=*\1:-8:M9W=E<^&DC MEMI8;V"5?+8'/&&#?.I#@&O]`/%7B_`<#<)5>(\RR6GG^%P>8Y9"6`G*C!J= M?&4J<,52E7H8FG[?"R:K44X0;G!)5J3:J0_RZ\%.!,S\2>.L/PEE'$-7AC&X M_*LYJ0S.G#$5$Z>&P%6M5P5:.&Q.$J_5L;"+P^(:J32I5&W0KI>SE_-1\$]* M^$6M?$WPIIWQT\4^*_!OPPGU.W'BG7?!OA^U\1ZY;V"R*TL4%K=:C8BSCN5! M@DU6&WUJ?3ED^UQZ%JGEFU;_`$(OV>;/X0Z=\&/AWI_P%GT:Y^$5EX9T^V\$ M3Z%="]LI-(2,%)&N2S337LLC22ZB]T?M;7SSM=`3EQ7\&'[;'P2TK]GC]JCX MT_"'0(Y8O#7A3Q?<'PS'//);BX=[B M8VADFDDD9I'_`'-_X-]_CUKUZ_Q@_9TUC4+B\T;1]-L?B5X-@N)))8]+6;4( M=$\3V=L&RMM:S7-WHUXL2,%>ZN+J39DEJ_#OI(<-5>-/#S+/$#*>*V<^%^>Y'EL%W%/(\-_$:3>9$GY;>JL?G/T=7*/TD,$XI\T<1X@M;WNN'>(VM%KO M;]-3^<36;[^T]8U?4O,,O]H:IJ%]YK+L:3[7=S3^84P-I?S-Q7`P3@@=*_J\ M_P"#>BSMU_9W^.M\L8%WUM)I>27@L_`_A^:VC()*XBDOKM@0`%*P^DXE'P@S2,'[BS#(HJS5G&.8X=Q3MHU[L7II=)K9'1]#ENIX\Y M+.HKU/[)XFF^9:QG+*Z_,_>NT_>DGULVGNS\R_\`@O1!#%^W%I+QQJCS_`SP M#+.RJ`99!XA\`;CCHK=*^I/^"]O_)\.B?]D(\!?^I-X]KY&_X) MB0S3?M[?LQ^3$TOD_$6*>7:,[(8M'U5I)&]%08+'L.:Z^%XQG]'"A&IK!^&. M8I\SZ+),7;7I:RMT6B1Q<92E3^EMB94KJ2\8LFM97?O9_E_-IW=VWW;;9RO_ M``4*'_&E5_>5'\S^F:GJ&C:EI^L:3>7.FZKI-[::CIFH6*6-70@J*]>\6?M'_'SQ[X?O_"?C7XP_$/Q5X9U4VAU+ M0==\4ZMJ6E7WV&^MM2L_M5G=7,D,WV74+.UO(-ZGR[FWAE7#QJ1+^S%;6]Y^ MTE^SW:7D$-U:7?QQ^$UM=6MQ$DUO<6\_CW0(IX)HI%:.6&:)GCEBD5DD1V5U M*G%?V!?\%=_AK\/=`_X)X_M!ZOH?@;PAH^JVA^$WV74M+\-Z/I]];_:/CC\- M+:;R+NULXIX?-MIIK>7RY%\R&62-LH[*?[HX]\1#P6"S6=7#4YY-4Q&;8#`1KTX5L'B*E1TZF)CB;4:V'DW224XR:E'_-?PP\) M\[XW\._%'B_+N,:^08'@?*,?C\QR6E0Q=2GG]+"9'F&:5,/4J4,?A*5-5J." MGA&Z^'Q<>6NY.#@G3G_$D_W3^'\Q7]'GQ_\`V/\`Q'^T!_P25_8]^+7P^TV7 M5_'7P*^'5U?ZCHEE"\VH:_\`#[6;V[;7UL8H\OO-/L=8M;14)ETY]<$ M.ZZ-O#-_.&_W3^'\Q7]]O_!,]%D_8'_9@1U5T;X96BNC*&5U;4M45E93P0P) M!!!!%?,?2-XJS#@G+N`>*,KY)8O*>-(UE1J-JEBJ%3)DDZV#Q5'B+),3@<= M13T=7!XVA0Q,82]RK[+V52]."6)]RL-T(IO$?[0O[*. MC)!KTWVO6?'OP=L8DCMM7G.)KO7?`4,2(EMJ$^)KG4O#KL8;NX9I]*:%I&LQ M_+K=VEU9W5U8WUO/97ME/+:W=I=0R6]S;7,$C13V]Q!*%EAFAD1HY8I%5XY% M964,I%>_A<3X<_2(X*=.K".(<5%U\/)TZ6>\,YG*&DZ=1*3IR3B_95X\^"Q] M*+A452'M:,/EL9A/%CZ*7B'&I2JSPW/*2PV*@JE;AOC#)Z=2/-3K4VU&K'E< M?;8:;IYAE5><:E*5*?L:]3_3!TG5],UO3-/UC1[^UU32=4LX+_3=2L9X[JRO MK*ZC6:VN;6XA+QS030NDD_^I-J5?MM M_P`$2?V\O$VB^-K/]C_XG:Y<:QX.\3K<3_!^_P!2F:>[\*>(XHGN;SPC#=2L MTK:!KT,;3Z78EBFEZO%,EH@BU:80?B3^TY_R<7\<_P#LK'C[_P!2;4J_./`/ MP^S3PU\1/$'AW,IQQ%)9/DN+RS,*<'"GF&6UL;CHT<0H-OV56,H5*&)H\TE2 MQ%&I&$ZE)TZL_P!:^DYXHY-XN^%/A9Q7E-.6$K//N(VHSA5HXG"8CEBZV%K4I3A2K>UHT^,\`_%[XH_"HZFWPV^('BSP,V ML"V&JGPOK=]HYU`6AE-J+O[%-$)_L_GS>5YF[R_-?;C<:]B\-?M=?M13^(_# M\,WQ^^+$L4VMZ5%)&_C;7&22.2_MU=&!NR"K*2I!&"#S7[.?\&^WA#PIXKN_ MVF!XH\,Z!XB%E;_#8V8US1]/U46IFD\6B8V_VZWG\GS1''YGE[=_EINSM%?T MKK\(?A2C*Z?#3P$KHP967PEH(964Y#*189#`X((Y!&1S3\3O'CAO@[C'.N&< M?X>8;/,7@:>!4\UJ8K`4YUWB\MPN+@W"ME.)JKV,*\:*O7E=4[QY4[17@W]& M?B[C_@'AWC'+/%7&<.8#,:F/E2R2E@\SJTL,L!F^+P511GA\\P=%_6*N$GB' MRX:G9UK2YY)R?<6)WVUJQ)+-;0,23DL6B4DG\3^=%650+TZ```=,<8[>,?&?B:/Q!HFL:CXB72/#FB MO!I0L(3J6GV^G7>IZKLG43-:VUYI8EC.P7T+#-?ZN>/'"V><9>'F.R#AW!?7 M\TQ68Y34IT/;X?#15*ACJ-2O5G6Q56C2C"E33G*\^9I6A&4FHO\`Q&^C1QIP MWX?^*V6\3\5YA_9F38+*<^IUL4L-B\7+VV)RVM1PU&%#!4,17G4KUI1IPM3Y M%*2=2<(7DO*_^"L6JV>J_P#!0#]H%K*3S4L=?L'_@W_TFYG_:Y^).MH#]CTWX`^(=-N&V$J+C6/'?P]N+ M4&3[J%DT:[(5N7"L5X1J_%7Q_P"./$GQ.\<^+/B%XLO#J7BCQMXBU7Q)K=V% MVB?5-9O9;VY\B(9\J!9)3#;0K\L-NL4*?*@K^MS_`((<_LF^(O@K\&O%GQF\ M?:/=Z)XK^-4VE#0]+U*W>VU"S\":$+F72;N:"4>;;G6[W4+N_C1O+>6S6R>2 M/`B8_)>+^+PO`O@)+AS&XFC/,*N09+PI@H*:OC,71I8*AC*E&+]]TJ6'P^)Q M#ERVA&-.,FI3A?[CP&P6.\2OI-PXMR[!UXY72XHXAXWS"HX2YMF&)P% M+$3BW!5JV*Q6#PL8<]YRE4G&,H4YG\K_`.T?_P`G%?'W_LM/Q2_]3K7J_H'_ M`.#?.Q_M3P1^U]IAP1J4WPVL#NZ#[9H_Q`M^<$$#]YR5/3WZ?S\_M(?\G%?' MW_LM?Q3_`/4YUVOZ&O\`@W7`.@_M4Y_Z#'PF_P#2'QW75XZR,\PXZA)=XRR'B&+7W/3Y;G\VWQ.T&;PM M\2/B!X:N(6@FT#QKXITAX7#J4_L_7+ZU48?Y\%8@5+$DJ023G-?T]?\`!O#K M\<_P;_:*\,K)&9=(^)OA77I(0K"5(O$?A:;3XI'<_(R2-X6F6-5^9&BE9QM= M*_*W_@L3^R_X@^`W[6'BKQS;:5-_"^LPV\@TR'6KD+_P`)1X"K8_!3K591ITJ] M+V6,PK565.,<5!0J3A'F:X_#?,\+X"?2-F^,UBA"=:OA:SKY?C8NA"K*>#G*I2A4ER)_3'_!=;64U3]N^_LD>- MF\.?"7X=Z/((PVZ-YO[;\0*DQ8!3(8]=C<%,KY3Q`_.'`\T_X(Y>%+CQ7^WO M\)F2-WB\-6?BKQ3/(%;RX4TO0;O8TKJ-J!Y)UC3>P#R,J`%B`?BS]I3X]^*O MVG?C;X^^-_C2WM++7?'.J0W;:;8-*]EI&G:=86ND:+H]I),3-+;Z9I-A8V*2 MR_O)A!YL@WNU?T(_\$"OV7_$&C6GQ$_:D\6Z/<:;IWB+3HO`/PPDOHFBDUBQ MCNEOO%OB*RCDVN-/2XMM.T33[Y5:&^F76X8W7[$WF&OT>IY3FE>C3S M*AP=A.&%3C4C)5\YS'!1P->EA7?]^J,ZN)Q#<%KAL-5JOEA%M=W`5%^+WTJ: M>>Y-0Q%;*<1X@8WC&56=*<'A\@RC,'F.&KXQ6_V9UZ=#!X5*H[+%XJEAUS3F MK_B1_P`%"R/^&Y?VJ@._QL\G^+]% MUB.!A8V_B:WTJRTOQ=H=Q<*H0:@-4L7UY48!I++6X"IE>"Y9?DO]AC]LKQ-^ MQ+\9A\4=%\-VGC/2]2T:Y\.>*?"MU?OI)U;1[B>&Y4V6JI;7W]GZA:W$*36L M\EC>0`[DDMI%8;>_'X&KXB?1]HY=PS*CC,9FW!N34,'2]M3I*>.R^GE\L1@9 MU9RC2I8B&(P=;"3=2<(4ZZ_>3A!.2\S+,PH>%'TI,1FO&$<1@,!D?B#G^(Q] M?ZO6JRAEN:5,QAAQIU*M7#2O3A.HU%_Z""YQR<^G MTK^8[_@XB^_^S=_US\;?^AZ57J-I_P`'#OP9-O$UY^SM\4(;IE!GBMO$_A6Z M@C<]5CN)5M'E7&,.UM"3GE!W_-O_`(*B?MJ>$_VW_A]\#_B+X2\&>(O!-CX> M\2>./#$VG>([S3;V[N)TM-%O3E?S7X+>%/B%PAXF\ M,9SQ'PSBLLRRE5S*A4Q=7$Y?5IQK5\FS"%&%L-C*\WSRT3C!QZMVU/Z[^D-X MW^%?'G@YQCD'"?&&"SC.*]')\32P-'!YK0J2H8;/\IJ5ZG-C,!AJ25.#YI1E M-3W48MIH_-S]EK_DYK]G3_LO'P@_]6!H%?V8_P#!8[_E'!^T7]?A!_ZOCX7U M_&=^RU_R4_P#K59*?COT:?^4?_I,_]DKGO_K%<0'\+C?=/^>]?VO?L4?M?_LT M?`/]BS]E/PG\9/C+X-^'OB._^#^G:U9:1XAN[FWO+G2Y]:UFVBOHTAM9U,#S MVUQ$IW@[XG&.,U_%"WW3^'3ZBOUR_;4^`7B:X_8A_8!_:0T;3+F^\,6OP7C^ M&7C.[MHFFCT+4(O$>NZWX8O=0"JWDVNLQW^J:?%=<017.F06\[QSWUHL_P"H M>-7"F2<;_P"HW#&?9EBLJPF:<38FG0Q.$GAX5I8ZED.:U\-AT\52K4E]8=.5 M*"Y'*I5E"E#WY13_`!SZ//&_$?AR_$CC+AC*,%G6.R;@_"5,5@\?#%5*$,MK M<3Y'A\9BW#!5J%=K"QJQK3DI\E.C&K5J?NZH6U_>V7AW0[VYGU*YM=,M7O+^>*.6TA0I:VL`OVF/`MC:Z(WQ6UO4_"OQ&TBT2.&TO/%]GIPU?2?$]K;Q M@".[UK3;;5H-=*JJ2WFGV=Z=US?73M^*W[-OQ_\`&G[+_P`9_!?QM\`1Z?<> M)/!MU>21V&JI-)I>JZ?JFGW6DZMI5^EO+!+]EOM-O;FW=HI8Y86=9X762)&7 MZD_;M_X*1_%7]NJW\&Z'XJ\,>&_`O@SP1>W>L:;X;\.2WMX;W7KZT%C)JVJ: MCJ,C33RV]H9[:P@@BMX+>&ZN2R2RRM+7YQPAX$\0^&OBID.;\)9GB,5P=/+L M12XBQ&98O"PQRKTZLZM2"IQC/]9X[^ MDMPKXO>"O$N1\=9/A,%Q_3S;"5N%,+E&`QM3!4HTJN`G',H9AB\1B/JE:-*6 M:X3'4I5HNOA*M*G2I5'5G*G\R_LK:UJ7A[]I;X$:SI/G_P!HV?Q7\#-;_96V MSYFU^QMY/+;(`(AFDSS]W(SSS'^TX"/VC/CH""#_`,+8\>Y!X/\`R,VI=#OAEJ]K\0O'.JM!(VGZ?I^ARFXTVRGN`I MCCO-8U1+6SL(23))(7EV^3!,\>M_P5H_9N\5_`7]L+XDZY=Z;!M>2*4:;=KXAF-[X@T/[00T46I>']=EO[26S:5ISIITS42BQ7\:C]I7%& M21\6EPR\5065P M=Q'/P,EQ@L'B7D%/Q$6%57V4O9PY\CCAZF/OLL+/%QHY=+$O]T\9&GA^=5;0 M?Z2?\&[-U;IJO[3MFTJ_:IK#X;W,,& M\Z"S\5^%;^VC(=@OE7<\&G2S!H]C,7LH-KL\:AP@D?\`E/QX\%_$+B+Q$S3B M3AS(JF%&2\)<6\34^'\YR+%9O"=#%X#-*M+$X;'9KBLRH8G#X MG!X+%8>2MC70G2G4A7A.C.3I.FXU)_T345\N?L??M0^'_P!L'X*Z1\;?#'AG M6O".D:OK.O:-%HNO7-C=ZA#+H-\;*:9YM/9K9HYG&^,*2RK\K45_)&9Y;CLF MS'&Y3F>'EA,PR[$UL'C<+.4)3P^)P\W3K4I2I2G3 MBGH?YY&Q?3]3_C2,H"G`].Y]:**_VQ:5GIT?Y?\``7W'_.TMUZH_JN_X)1_L M;?LR>)O#EC\3?$WPA\/>)?&NFS^=8:IXBNM0O!%W#%7*\JRW+:N89?3Q&/J8#`X7!U,;B-O;XN>'I4Y8FM9M M>UK.<[-KFU/\Y3]I``_M%?'W/;XU?%/U_P"AYUZOZ&?^#=D`:!^U3C_H,_"; M];'QX?YT45_7&JKYD\TLKXR[LV3117Y-]#[%XJ;XPP4\3B)8.BLLK MT<)*M4EAJ5>M/$1JUJ=!R=*%6K&G3C4J1@ISC""DVHJW[A]/7`8&G_J!F,,' MA(9AB*F<86OCH8>C'&5\-0A@9T+O"EQ#?7UQHE[=ZE:6ES<6*QS6WVG^S+V MQFN(%D&9+2:5[2X7,=Q#+&2I_O+T#0]&\,Z-I7A[P]I=CHNAZ/9PZ=I6D:9; M16>GZ?8VL2QV]K:6L"I###"@"HB*`!117QWTM\7BY\;Y-@I8K$2P='(%A MF%?BC$X6OCHX>C'&5L-0P6"J4,/5Q2@J]2A1G5JSI4IS=.G.I.4(ISDWY[\; M?A%\-/C3X`U?P5\5/!>A^-_#%S!+,^E:W:F5(;A$(CNK*YA>&]T^\CR?+O+" MYMKJ//R2K7\(G[;7PK\!?"/XS:UX4^'F@_\`"/:!:7^K0V^GC4]9U41QVUXL M<"_:M;U'4KQO+1BN7N&9NK%C@T45Z7T2[%]/U/^-?07B``?LQ_#WV^* MOCK'_@C\.T45_=&;)>VR33_F2']H_1I_Y1_^DO\`]DCG3_\`-*XA/X7V4`$@?S]: M_O$_X)_^$/"_CW_@F_\`L]^#O&F@Z7XG\+:_\([>PUG0M9M(K[3=1M)=0U0M M#G3K4*W`M6E6HU81J4J MM*IGF40J4ZM.:<*E.<)2A.$TXRBW&2:;1_'?^W)\./!7PG_::^*'@;X?:''X M<\*:+K/EZ7H\-YJ-]#9QR(LC1Q3ZI>7UX8PS-L1[AUC7"1A4`4?-/A.PM-3\ M4^'=.OHO/LK_`%?3;6[A\R2/S8+BZCCE3S(7CE3>C$;HW1USE6!P:**_H'A7 M$5\1P1P_BJ]>M6Q5;AS+ZU7$U:DZE>K6GEU&AA*%&G2PU'#PSBM3A0I4*<8TJ=&-- M*G&E""A&"45%121_H(_L??!#X3_`[X(^$M%^%'@;1O!=AK>EV&MZW_9JW,]] MK.K3VJ"2_P!7U74;B]U74[@*/+B>^O9_(B_=0"./Y:]"^.GP8^%?QR\`ZKX. M^+?@70/'?APP2W46GZY:F4VEVL)"WFG7L#P:AIEXG&R[T^ZMKE<`K*"!117^ M2.89IF;XFQ>:O,<>\T6<5:ZS)XO$/'JM'%.,:RQGM/K'M8I)*I[3G222=D?[ MI97DN3K@_`9(LIRQ9-+(\-AGE"P&%65O#SPD'.@\![+ZHZ,FVY4G2Y)-MN+N MS^$K]M?X6^!/A)\9-;\*_#W0O^$?T&TU+4X+>P&IZQJHCBMQ8&%!I6Q&( MJ3K5ZLW!-SJ5:DI5)S;6LI2;?5G^$WB)A<-@N.N)L)@L-0PF%P^<8JE0PV%H MT\/AZ-.-2T:=*C2C"G3A%:1A",8I;(_ME_X(A\?L#^"?^QZ^(W_I^8_SHHHK C_*WQ9_Y.;QY_V56=?^IU4_VN\#?^3.>&/_9#\-_^JO#G_]D_ ` end